Summary of Cerus Corporation Conference Call Company Overview - **Company**: Cerus Corporation - **Industry**: Medical Devices, specifically in transfusion medicine - **Mission**: To make the INTERCEPT Blood System the global standard of care in transfusion medicine, ensuring safety and availability of the blood supply [4][5] Key Points Market Position and Financial Performance - Cerus has experienced a **5x increase in sales over the last 10 years**, with current revenue guidance for the year set between **$224 million and $228 million** [6][7] - The company operates in **over 40 countries** and holds a **first-mover advantage** in the market with significant barriers to entry for competitors [7] Growth Drivers - **U.S. Market**: Approximately **60% of revenue** comes from the U.S., with a **mid-60% market share** in the platelet franchise [13][14] - **BCA Agreement**: A partnership with Blood Centers of America, representing about **50% of the U.S. market by volume**, aims to enhance penetration and adoption of INTERCEPT technology [14][24] - **International Expansion**: Germany is highlighted as a key market, with ongoing trials that could lead to significant growth in 2027 [16][46] Product Development - **INTERCEPT Fibrinogen Complex (IFC)**: Currently a U.S.-only product, with plans for international expansion. The market for IFC is expected to grow significantly as clinical appreciation increases [13][51] - **Red Blood Cells**: Anticipated approval for INTERCEPT Red Blood Cells in 2027, which could drive further growth [63][66] Market Dynamics - The **plasma market** is primarily international, with ongoing partnerships to explore adoption in Canada and other regions [29][31] - The **IFC market** is projected to grow as clinicians recognize the benefits of earlier access to fibrinogen, with a potential market size of **$300 million** in the U.S. [51][54] Challenges and Considerations - The company acknowledges the complexity of the regulatory environment and the need for ongoing clinical data to support product adoption [43][66] - Geopolitical factors, particularly in the Middle East, are monitored closely as they could impact international operations [48][46] Future Outlook - Cerus is positioned for **sustained double-digit growth** through the end of the decade, with multiple growth initiatives in place across various markets [64][66] - The company is optimistic about the potential for increased market share in the U.S. platelet market, aiming for **70%+ share** in the near term [39][38] Additional Insights - The company has a strong financial foundation, which supports its global growth strategy [7] - There is a focus on leveraging existing partnerships and expanding manufacturing capabilities to meet growing demand [61][62] - The INTERCEPT technology is seen as a unique solution that enhances blood safety, with potential applications in adjacent markets [36][57]

Financial Performance & Guidance - Cerus is raising its full-year 2024 product revenue guidance to $177 - $179 million, anticipating a 12-14% increase compared to full-year 2023 product revenue[13] - The bottom end of the 2024 IFC guidance range has been raised to $9 - $10 million, from the prior $8 - $10 million[13] - In Q3 2024, Non-GAAP Adjusted EBITDA reached $4.4 million[32] Product & Market - The global addressable market for INTERCEPT products is estimated at $1.3 billion, with potential growth to over $1.5 billion in 5-7 years[22] - The U S addressable market is $150 million, with potential growth to over $200 million in 5-7 years[22] - Cerus' preliminary 2023 product revenue was $156 million[22] Strategic Initiatives - Cerus has a new BARDA contract for INTERCEPT RBCs[11] - The company submitted a CE Mark for its LED Illuminator[11] - Cerus is focused on adjusted EBITDA and operating cash flow goals[25]